Legend Biotech Corporation
(NASDAQ:LEGN)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen re...

Website: https://legendbiotech.com/

Founded: 2014

Full Time Employees: 800

CEO: Yuan Xu

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-05-18	2022-12-31	2022-06-30	2021-08-23

revenue												33,915,000
yoy
qoq
license revenue	10,481,000	35,338,000	120,123	103,027	12,181	-12	35,172	15,115
collaboration revenue	261,831,000	219,717,000	314,563	171,735	78,481	79,435	170,369	58,152	36,280		11,937,000
other revenue	18,000	3,000	6,033	5,752	3,329	41	138	63	56		34,000
total revenue	272,330,000	255,058,000	440,719	280,514	93,991	79,464	205,679	73,330	36,336		11,971,000
cost of collaboration revenue	-113,264,000	-94,872,000
cost of license and other revenue	-2,042,000	-3,119,000	-13,693	-10,734	-5,638
research and development expenses	-113,148,000	-98,302,000	-309,112	-213,590	-100,964	-105,683	-276,535	-95,791	-84,889		-68,827,000	-154,529,000
administrative expenses	-34,721,000	-32,594,000	-102,582	-67,282	-31,929	-28,707	-78,062	-27,753	-22,205		-18,050,000	-17,991,000
selling and distribution expenses	-52,607,000	-48,052,000	-98,556	-54,286	-24,223	-33,677	-60,481	-21,429	-17,954		-27,440,000	-30,199,000
loss on asset impairment
operating income	-43,452,000
yoy
qoq
operating margin %	-Infinity%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	0%
finance costs	-5,636,000	-5,222,000	-16,463	-10,959	-5,475	-5,820	-15,974	-5,185	-5,113		-1,643,000	-90,000
finance income*	9,661,000	10,433,000
other income/(expense), net*	354,000
income before tax	-39,073,000	-124,798,000	-198,644	-77,758	-59,788	-146,812	-373,306	-198,838	-111,973		-193,071,000	-172,482,000
income tax expense	-616,000	-582,000	-4,666	-231				-290			-157,000
net income	-39,689,000	-125,380,000
yoy
qoq	-68.35%
net income margin %	-Infinity%	-Infinity%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	0%
loss per share
basic	-0.11	-0.34
diluted	-0.11	-0.34
other comprehensive (loss)/income
other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods:
exchange differences on translation of foreign operations	-877		3,374	-58,528		43,338	-13,705					3,305
other comprehensive (loss)/income, net of tax	-877
total comprehensive loss	-40,566
other (expense)/income, net*		-108,128,000
weighted-average shares outstanding
basic		368,271,125
diluted		368,271,125
collaboration cost of revenue			-146,966	-94,456	-49,101	-32,450	-111,764	-32,672	-35,613		-16,939,000
other income and gains			49,148	93,037	64,091	8,314	49,812	16,433	8,199		1,856,000	2,390,000
other incomes			-1,139	-2	-540	-28,253	-231	-21	-10,734		-8,099,000	-4,378,000
fair value loss of warrant liability								-105,750				-1,600,000
loss for the period			-203,310	-77,989	-59,793	-93,359	-373,436	-199,128	-112,101		-193,228,000	-172,483,000
attributable to:
ordinary equity holders of the parent			-203,310	-77,989	-59,793	-144,818	-373,436	-199,128	-112,101		-193,228,000
loss per share attributable to ordinary equity holders of the parent
basic			-0.56	-0.21	-0.16	-0.4	-1.07	-0.57	-0.34
diluted			-0.56	-0.21	-0.16	-0.4	-1.07	-0.57	-0.34
other comprehensive income/
other comprehensive income that may be reclassified to profit or loss in subsequent periods:
exchange differences:
net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods			3,374
other comprehensive income/(loss) for the period, net of tax			3,374
total comprehensive loss for the period			-199,936	-136,517		-96,785.25	-387,141					-169,178
other comprehensive (loss)/ income
net other comprehensive (loss)/ income that may be reclassified to profit or loss in subsequent periods				-58,528		-3,426.25	-13,705
other comprehensive (loss)/ income for the period, net of tax				-58,528		-3,426.25	-13,705
us’000, except share and per share data
fair value gain of warrant liability
ordinary shares used in loss per share computation
basic					364,010,429			350,517,429	330,497,072
diluted					364,010,429			350,517,429	330,497,072
fair value gain/(loss) of warrant liability						-21,437.5	-85,750		20,000
income tax benefit/						1,994	-130
other comprehensive income
us’000, except per share data
income tax (expense)/credit									-128
fair value gain/loss of warrant liability											-65,900,000
loss per share attributable to ordinary equity holders of the parent:
ordinary shares – basic											-0.62
ordinary shares – diluted											-0.62
shares used in loss per share computation:
fair value loss of convertible redeemable preferred shares
income tax credit/												-1,000
equity holders of the parent												-172,483,000
loss per share attributable to ordinary equity holders of the parent
ordinary shares—basic and diluted												-0.63
net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods												3,305
other comprehensive (loss)/income for the period, net of tax												3,305

Balance Sheets:

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2025-03-11	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-05-18	2023-03-31	2023-03-30	2022-12-31	2022-07-25	2022-06-30	2022-06-01	2022-03-18	2021-12-31	2021-12-14	2021-11-16	2021-09-30	2021-08-23	2021-06-30	2021-05-18	2021-03-31	2021-03-18	2020-12-31	2020-11-16	2020-09-30	2020-08-31	2020-06-30

non-current assets
property, plant and equipment	111,403,000	106,381,000	98,810	99,288	99,288	104,031	105,018	105,278	108,725	109,503	110,978	110,045	110,045	105,168,000	105,168	156,005	106,181,000	156,005,000	145,724,000	145,724	141,071	141,071,000	141,071,000	135,216	135,216,000	122,905,000	122,905,000	113,091,000	113,091	96,125,000	96,125,000	88,589,000	88,589,000
right-of-use assets	142,338,000	127,217,000	107,224	101,932	101,932	99,452	114,718	80,179	80,502	74,811	78,497	80,459	80,459	55,590,000	55,590	7,393	39,423,000	7,393,000	7,186,000	7,186	7,561	7,561,000	7,561,000	7,312	7,312,000	7,547,000	7,547,000	8,009,000	8,009	8,077,000	8,077,000	7,786,000	7,786,000
collaboration prepaid leases	206,213,000	198,646,000	182,613	172,064	172,064	172,981	144,552	166,344	151,216	135,997	119,173	93,548	93,548	65,276,000	65,276
other non-current assets*	10,990,000	5,659,000
total non-current assets	470,944,000	440,040,000	396,857	386,236	386,236	385,788	373,351	361,315	350,810	330,538	317,797	293,962	293,962	231,844,000	231,844	177,811	186,800,000	177,811,000	169,615,000	169,615	160,403	160,403,000	160,403,000	154,291	154,291,000	140,179,000	140,179,000	128,149,000	128,149	105,919,000	105,919,000	99,474,000	99,474,000
current assets
collaboration inventories	29,184,000	35,589,000	30,933	23,903	23,903	23,548	18,870	22,146	19,433	18,014	15,196	12,176	12,176	10,354,000	10,354		8,158,000
trade receivables	1,236,000	27,584,000	369	6,287	6,287	705	13,064	3,307	100,041	20	15,064	56	56	90,000	90	50,451	461,000	50,451,000	50,410,000	50,410	1,501	1,501,000	1,501,000	15,000	15,000,000			74,978,000	74,978
prepayments, other receivables and other assets***	218,993,000
time deposits	713,698,000			4,362	4,362	4,509	4,400	4,387	4,362	4,268	4,209	4,366	4,366	54,016,000		4,726	4,470,000	4,726,000	4,705,000	4,705	217,710	217,710,000	217,710,000	174,644	174,644,000	50,000,000	50,000,000	50,000,000	50,000	125,559,000	125,559,000	75,559,000	75,559,000
cash and cash equivalents	278,893,000	266,586,000	441,702	286,749	286,749	459,277	201,253	897,571	1,277,713	963,470	1,233,213	660,050	660,050	786,031,000	786,031	377,786	379,776,000	377,786,000	688,938,000	688,938	338,334	338,334,000	338,334,000	488,215	488,215,000	412,296,000	412,296,000	455,689,000	455,689	449,381,000	449,381,000	562,391,000	562,391,000
total current assets	1,242,004,000	1,249,874,000	1,218,792	1,283,918	1,283,918	1,350,037	1,424,832	1,413,792	1,497,799	1,508,796	1,612,862	915,397	915,397	1,099,119,000	1,099,119	862,705	835,945,000	862,705,000	948,752,000	948,752	653,362	653,362,000	653,362,000	720,834	720,834,000	475,074,000	475,074,000	592,858,000	592,858	602,720,000	602,720,000	673,391,000	673,391,000
total assets	1,712,948,000	1,689,914,000	1,615,649	1,670,154	1,670,154	1,735,825	1,798,183	1,775,107	1,848,609	1,839,334	1,930,659	1,209,359	1,209,359	1,330,963,000	1,330,963	1,040,516	1,022,745,000	1,040,516,000	1,118,367,000	1,118,367	813,765	813,765,000	813,765,000	875,125	875,125,000	615,253,000	615,253,000	721,007,000	721,007	708,639,000	708,639,000	772,865,000	772,865,000
current liabilities
trade payables	102,455,000	75,361,000	58,143	38,594	38,594	26,906	39,490	39,485	20,160	17,173	21,544	29,811	29,811	32,893,000	32,893	9,712
other payables and accruals	147,183,000	138,836,000	116,810	166,180	166,180	164,864	169,531	136,012	132,802	144,651	165,519	146,378	146,378	184,109,000	184,109	96,055	116,842,000	96,055,000	123,464,000	123,464	87,445	87,445,000	87,445,000	109,183	109,183,000	80,096,000	80,096,000	99,168,000	99,168	67,889,000	67,889,000	60,429,000	60,429,000
lease liabilities	7,374,000	5,906,000	5,341	4,794	4,794	4,342	3,325	3,116	3,175	2,915	3,558	4,595	4,595	3,563,000	3,563	883	2,122,000	883,000	911,000	911	1,116	1,116,000	1,116,000	1,178	1,178,000	1,460,000	1,460,000	1,464,000	1,464	1,445,000	1,445,000	1,314,000	1,314,000
tax payable	10,108,000	11,550,000	14,009	20,671	20,671	11,067	6,566	7,273	7,203	9,853	10,326	9,940	9,940	9,772,000	9,772		9,339,000
contract liabilities	22,576,000	33,178,000	39,535	46,874	46,874	63,161	74,845	63,251	53,010							65,560		65,560,000	60,644,000	60,644	55,816	55,816,000	55,816,000	56,139	56,139,000	54,456,000	54,456,000	55,014,000	55,014	46,789,000	46,789,000	46,312,000	46,312,000
other current liabilities**	1,003,000
collaboration interest-bearing advanced funding	142,873,000	310,264,000	305,745	301,196	301,196	296,623	291,559	286,396	281,328	275,906	270,614	265,864	265,864	260,932,000	260,932		189,218,000
total current liabilities	433,572,000	265,482,000	234,373	277,645	277,645	270,894	294,302	249,675	216,418	175,222	201,382	238,181	238,181	297,788,000	297,788	225,530	259,756,000	225,530,000	280,266,000	280,266	275,369	275,369,000	275,369,000	261,101	261,101,000	145,942,000	145,942,000	161,167,000	161,167	123,522,000	123,522,000	115,031,000	115,031,000
non-current liabilities
collaboration interest-bearing advanced funding long term	171,930,000
lease liabilities long term	88,061,000	71,742,000	51,724	44,613	44,613	45,626	44,042	45,174	44,169	41,687	44,444	44,302	44,302	20,039,000	20,039
other non-current liabilities**	8,125,000
total non-current liabilities	268,116,000	388,893,000	363,527	351,963	351,963	348,824	344,879	361,373	380,820	324,476	322,246	318,021	318,021	288,863,000	288,863	376,423	200,357,000	376,423,000	366,895,000	366,895	312,530	312,530,000	312,530,000	274,105	274,105,000	262,860,000	262,860,000	279,585,000	279,585	250,217,000	250,217,000	256,833,000	256,833,000
total liabilities	701,688,000	654,375,000	597,900	629,608	629,608	619,718	639,181	611,048	597,238	499,698	523,628	556,202	556,202	586,651,000	586,651	601,953	460,113,000	601,953,000	647,161,000	647,161	587,899	587,899,000	587,899,000	535,206	535,206,000	408,802,000	408,802,000	440,752,000	440,752	373,739,000	373,739,000	371,864,000	371,864,000
equity
share capital	37,000	37,000	37	37	37	37	37	36	36	36	36	33	33	33,000	33	31	31,000	31,000	31,000	31	29	29,000	29,000	29	29,000	27,000	27,000	27,000	27	26,000	26,000	26,000	26,000
reserves	1,011,223,000	1,035,502,000	1,017,712	1,040,509	1,040,509	1,116,070	1,158,965	1,164,023	1,251,335	1,339,600	1,406,995	653,124	653,124	744,279,000	744,279	438,532	562,601,000	438,532,000	471,175,000	471,175		225,837,000	225,837,000			206,424,000	206,424,000
total equity	1,011,260,000	1,035,539,000	1,017,749	1,040,546	1,040,546	1,116,107	1,159,002	1,164,059	1,251,371	1,339,636	1,407,031	653,157	653,157	744,312,000	744,312	438,563	562,632,000	438,563,000	471,206,000	471,206	225,866	225,866,000	225,866,000	339,919	339,919,000	206,451,000	206,451,000
total liabilities and shareholders' equity	1,712,948,000	1,689,914,000
intangible assets		2,137,000	2,082	2,160	2,160	2,507	2,772	3,152	4,061	4,009	2,465	2,289	2,289	3,409,000	3,409	4,517	4,624,000	4,517,000	4,684,000	4,684	5,432	5,432,000	5,432,000	4,681	4,681,000	4,081,000	4,081,000	2,852,000	2,852	1,042,000	1,042,000	978,000	978,000
prepayments, other receivables and other assets		219,076,000	182,040	130,975	130,975	112,801	100,628	85,603	69,251	66,569	66,573	51,761	51,761	61,755,000	61,755	16,651	42,143,000	16,651,000	12,754,000	12,754	13,838	13,838,000	13,838,000	11,170	11,170,000	10,425,000	10,425,000	10,007,000	10,007	24,662,000	24,662,000	33,517,000	33,517,000
pledged deposits		70,000	70	70	70	583	431	359	357	356	1,246	1,283	1,283	1,270,000	1,270	1,448	1,402,000	1,448,000	1,444,000	1,444	456
government grants		651,000	535	532	532	554	545	538	68	630	435	457	457	451,000	451	320	315,000	320,000	304,000	304	299	299,000	299,000	300	300,000	281,000	281,000	283,000	283	2,033,000	2,033,000
advance payments for property, plant and equipment			545	374	374	376	295	563	451	419	1,061	2,193	2,193	914,000	914	258	191,000	258,000	2,168,000	2,168	1,766	1,766,000	1,766,000	2,197	2,197,000	1,663,000	1,663,000	224,000	224	675,000	675,000	2,121,000	2,121,000
other non-current assets			5,583	6,056	6,056	1,932	1,596	1,412	1,493	1,531	1,414	1,062	1,062	1,487,000	1,487	4,912	31,911,000	4,912,000	5,148,000	5,148	4,573	4,573,000	4,573,000	4,885	4,885,000	3,983,000	3,983,000	3,973,000	3,973
total ordinary shareholders’ equity			1,017,749	1,040,546	1,040,546	1,116,107	1,159,002	1,164,059	1,251,371	1,339,636	1,407,031	653,157	653,157	744,312,000	744,312	438,563	562,632,000	438,563,000		471,206	225,866	225,866,000	225,866,000	339,919	339,919,000	206,451,000	206,451,000
total liabilities and equity			1,615,649	1,670,154	1,670,154	1,735,825	1,798,183	1,775,107	1,848,609	1,839,334	1,930,659	1,209,359	1,209,359	1,330,963,000	1,330,963	1,040,516	1,022,745,000	1,040,516,000	1,118,367,000	1,118,367	813,765	813,765,000	813,765,000	875,125	875,125,000	615,253,000	615,253,000		721,007	708,639,000	708,639,000	772,865,000	772,865,000
financial assets at fair value through profit or loss							42,201	150,449	663	185,792	185,756	185,705	185,705	185,603,000	185,603	99,995		99,995,000			50,040									1,175,000	1,175,000
other non-current liabilities						27		30	56	119	152	224	224	233,000	233	356	314,000	356,000	396,000	396	991	991,000	991,000	554	554,000	554,000	554,000	554,000	554
warrant liability												47,000	47,000	67,000,000	67,000	53,000	118,900,000	53,000,000	87,900,000	87,900	119,100	119,100,000	119,100,000	83,300	83,300,000
financial assets measured at amortized cost																		29,974,000	29,937,000	29,937	29,849	29,849,000	29,849,000
inventories																2,895		2,895,000	1,749,000	1,749	1,634	1,634,000	1,634,000	1,700	1,700,000	2,097,000	2,097,000	1,800,000	1,800	1,513,000	1,513,000	1,668,000	1,668,000
financial assets measured at amortised cost																29,974
interest-bearing loans and borrowings																126,714		126,714,000	120,462,000	120,462	70,540	70,540,000	70,540,000	17,310	17,310,000
collaboration lease receivables																	671,000
trade and notes payables																	12,238,000	9,712,000	7,043,000	7,043	11,593	11,593,000	11,593,000	11,001	11,001,000	9,649,000	9,649,000	5,238,000	5,238	7,399,000	7,399,000	6,976,000	6,976,000
reserve																					225,837			339,890	339,890,000
financial assets at fair value through profit and loss																						50,040,000	50,040,000
pledged short-term deposits																						456,000	456,000	256	256,000	256,000	256,000	384,000	384	430,000	430,000	256,000	256,000
financial investment measured at amortized cost																								29,849	29,849,000
reserves/																												280,228,000	280,228			400,975,000	400,975,000
total ordinary shareholders’ equity/																												280,255,000	280,255			401,001,000	401,001,000
total equity/																												280,255,000	280,255			401,001,000	401,001,000
total liabilities and equity/																												721,007,000
deferred tax assets
reserves /																														334,874,000	334,874,000
total ordinary shareholders’ equity /																														334,900,000	334,900,000
total equity /																														334,900,000	334,900,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-07-25	2022-03-31	2021-12-14	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30

cash flows from operating activities
loss before tax	-39,073,000	-223,828,870	-99,130	40,511	-120,886	-17,970	-59,788	-146,812	-62,495			-41,087		-297,874
adjustments for:
finance income	-9,661,000	-22,476,944	-12,056	-13,654	-16,631	-17,049	-13,870	-17,302	-18,420			-458		-548
finance costs	5,636,000	10,277,939	5,061	5,152	5,504	5,484	5,475	5,820	5,676			994		298
provision for inventory reserve	865,000	-4,862,202	-3,798	5,909	403	4,668	1,757
depreciation of property, plant and equipment	2,146,000	4,564,716	2,284	2,743	2,381	2,780	2,796	2,726	2,675			3,179		8,159
depreciation of right-of-use assets	3,961,000	6,255,213	2,787	3,687	2,777	2,223	2,041	2,143	1,997			257		1,087
foreign currency exchange loss	210,000	165,129,808	55,192	-110,457	61,815	-11,648	-49,056	38,360	-17,156			1,494		2,726
equity-settled share-based compensation expense	15,015,000	34,627,054	15,946	13,388	15,111	21,739	18,703	12,589	12,377			5,674
other, net*
decrease in trade receivables	25,790,000	-20,285,918	5,918	-5,582	12,359	-9,757	96,734	-99,050	15,044			-39		73,499
increase in prepayments, other receivables and other assets	-1,218,000	-84,369,414	-48,586	-17,799	-13,588				101			-3,671		-3,656
increase in collaboration inventories	5,373,000	-6,016,768	-3,232	-6,265	-5,081	-1,392	-4,470		-2,818
increase in trade payables^
increase in other payables and accruals^**
decrease in contract liabilities	-10,345,000	-18,492,963	-9,037		6,668	-20,349	-23,826							-37,050
other assets and liabilities, net***
interest income received	3,279,000	37,890,043	14,957	9,817	8,235	5,806	13,479	14,372	16,281
income tax paid	-2,055,000			-654	-49	-918	71							-1
net cash from operating activities	28,801,000	-116,692,246	-103,754	-82,078	-75,822	-1,651	15,518	-95,645	-60,848
capital expenditures	-5,005,000	-11,223,998	-2,002	-2,378	-2,065	-3,419	-6,243	-4,345	-5,377
free cash flows	23,796,000	-127,916,244	-105,756	-84,456	-77,887	-5,070	9,275	-99,990	-66,225
cash flows from investing activities
purchase of property, plant and equipment	-5,005,000	-11,223,998	-2,002	-2,378	-2,065	-3,419	-6,243	-4,345	-5,377			-12,118		-40,407
prepayment to collaborator for collaboration assets	-8,679,000	-21,643,642	-15,358	-5,747	-15,415	-17,154	-16,541	-18,566	-27,200
purchase of financial assets measured at fair value through profit or loss				551	760	-252	-150,308					-100,000
cash received from withdrawal of financial assets measured at fair value through profit or loss				-551	41,637
cash receipts of investment income				-7	621	1,183	663	2,408	2,365
purchases of time deposits
maturities of time deposits
net cash from investing activities	-20,001,000	90,858,360	256,640	-87,842	329,077	-695,631	-396,148	407,509	-209,072
cash flows from financing activities											-286		25,000				207,000
proceeds from exercise of share options	1,272,000	1,715,556	1,444	603	5,409	2,115	1,589	621	2,682			459
principal portion of lease payments	-602,000	-2,039,223	-777	-936	-1,164	-1,160	-758	304	-1,721			-434		-997
net cash from financing activities	670,000	-323,667	667	-333	4,245	955	831	925	961
effect of foreign exchange rate changes	2,837,000	5,839,600	1,400	-2,275	524	9	-343	1,454	-784	2,584	-2,572	10	10,000	-44	-759,715	378,000	337,000	-324,380	437,000
net decrease in cash and cash equivalents	18,148,000										-123,409	-311,162	-311,162,000
cash and cash equivalents at beginning of year	0	286,462,251	286,749	0	0	0	1,277,713	0	0
cash and cash equivalents at end of period	12,307,000	266,144,298	441,702		258,024	-696,318	897,571		-269,743			377,786		338,334
analysis of balances of cash and cash equivalents
cash and bank balances	25,036,000	966,619,550	1,005,450	-90,377	-36,977	97,795	1,156,674	70,104	-91,813	664,417	670,065	667,465	667,465,000	556,500	555,836,885	200,563,000	462,552,000	-574,863,927	-62,836,000
less: pledged deposits	0	69,930	70	-513	152	72	359	1	-890	-37	1,283	1,448	1,448,000	456
time deposits	12,729,000	700,405,322	563,678	82,664	-295,153	794,041	258,744	-244,140	178,820	91,291	8,732	288,231	288,231,000	217,710	217,535,356	124,644,000	50,000,000	-125,509,000	50,000,000
cash and cash equivalents as stated in the statement of financial position	12,307,000	266,144,298	441,702	-172,528	258,024	-696,318	897,571	314,243	-269,743	573,163	660,050	377,786	377,786,000	338,334	337,845,785	75,919,000	412,296,000	-448,925,311	-113,010,000
cash and cash equivalents as stated in the statement of cash flows	12,307,000	266,144,298	441,702	-172,528	258,024	-696,318	897,571	314,243	-269,743	573,163	660,050	377,786	377,786,000	338,334	337,845,785	75,919,000	412,296,000	-448,925,311	-113,010,000
loss on asset impairment		969,030	970
loss on disposal of property, plant and equipment		249,947	53	0	0	0	2	3	82			20
amortization of intangible assets		227,872	128	366	314	366	885	482	499					960
fair value gains on financial assets measured at fair value through profit or loss						248	-449
deferred government grant		-276,866	-134	-135	-137	-136	-157	-144	-124			-77		-219
decrease in other non-current assets		770,527	473				77					244
government grant received				0	0							91		79
increase in trade payables*		36,015,490	19,510
increase in other payables and accruals*		-17,723,365	-38,635
decrease in other non-current liabilities				-26	27	-31	-25		-1,229			-40
increase in pledged deposits				1	-150
cash from operations		-138,250,714	-106,286	-90,636	-83,582	-6,216	2,384	-109,950	-76,719			-78,966		-129,185
interest on lease payments		-1,176,501	-499	-605	-426	-323	-416	-375	-410			-31		-105
addition in time deposits		-4,149,900,000	-100,000	-313,999	-54,813	-1,472,198	-721,990	-1,914,455	-2,516,671			-209,971
decrease in time deposits		4,273,626,000	374,000	233,773	358,352	688,044	498,273	2,159,986	2,336,985			90,000		100,000
increase in other non-current liabilities														437
income tax received			-11,926
note			2,025	0	0	0	2,024	0	0
proceeds from disposal of property, plant and equipment							-2
net increase in cash and cash equivalents			153,553	-170,253	257,500	-696,327	-379,799	312,789	-268,959					-117,311
income before tax											-111,973		-41,087,000			-91,583,000	-80,899,000		67,822,000
cash and cash equivalents at beginning of the period											786,031		688,938,000				455,689,000		393,594,000
cash and cash equivalents at end of the year
legend biotech corporation reconciliation of ifrs to non-ifrs
us’000
net income
depreciation and amortization
share based compensation
impairment loss
unrealized foreign exchange loss
fair value loss of warrant liability
adjusted net loss
ani per share:
ani per share - basic
ani per share - diluted
loss on impairment asset
fair value gains on financial assets measured at fair value change through profit or loss
increase in contract liabilities						12,063	11,645					9,213
purchase of intangible assets								-2,504	-96			-411		-3,555
cash received from withdrawal of financial assets measured at amortized cost
decrease in pledged deposits
proceeds from issuance of ordinary shares for institutional investors, net of issuance cost
proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs								0
proceeds from exercise of warrant by warrant holder, net of issuance cost								0	0
cash and cash equivalents at end of year
increase in other non-current assets					-343									-600
increase in trade payables					-12,725	-13	19,298	3,018	-4,371			2,669
increase in other payables and accruals					2,107	36,808	10,878	-10,025	-8,521					63,795
decrease/(addition) of pledged short-term deposits
proceeds from issuance of ordinary shares for institutional investors, net of issuance costs									0
cash flows from, operating activities
proceeds from registered direct offering, net of issuance costs
decrease in prepayments, other receivables and other assets							-16,266
provision for inventory reserve*
decrease in collaboration inventories*
purchase of financial assets measured at amortized cost														-29,849
proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor														300,000
fair value gain of warrant liability												-34,900
fair value losses on financial assets measured at fair value through profit or loss
cash flows used in operating activities											-141,053		-78,687,000				-26,787,000
cash flows used in investing activities											17,930		-232,500,000				-17,150,000		-49,411,000
cash and cash equivalents at end of the period											660,050		377,786,000				412,296,000		-113,010,000
fair value loss of convertible redeemable preferred shares
decrease in collaboration inventories
repayment of cash advances from related parties
proceeds from convertible redeemable preferred shares
proceeds from issuance of ordinary shares for initial public offering, net of issuance costs
proceeds from issuance of ordinary shares relating to private placement by genscript
payments of expenses for issuance of convertible redeemable preferred shares
reversal of provision for the impairment of trade receivables
amortisation of intangible assets												491
fair value loss on financial assets measured at fair value change through profit or loss												5
increase in inventories												-1,146
decrease in other payables and accruals												-21,879
finance income received												310		373
net cash flows from operating activities												-78,687		-128,918
net cash flows from investing activities												-232,500		-291,495
net cash flows from financing activities												25		303,102
cash and cash equivalents at beginning of period												688,938		455,689
fair value (gain)/ loss of warrant liability
foreign currency exchange loss/(gain)
decrease/(increase) in trade receivables
(increase)/decrease in prepayments, other receivables and other assets
decrease/(increase) in other non-current assets
(increase)/decrease in collaboration inventories
increase/(decrease) in trade payables
increase/(decrease) in other non-current liabilities
(reversal of)/provision for the impairment of trade receivables
decrease in inventories														166
increase in trade and notes payables														6,355
interest on loan from related party
net cash flow used in operating activities
cash advances to related parties
collection of cash advances to related parties
addition in pledged deposits
proceeds from cash advances from related parties
proceeds from loans from related parties
repayments of loans from related parties
reversal of the impairment of trade receivables														-22
loss from disposal of property, plant and equipment														977
fair value loss of warrant lability														37,400
fair value gains on financial assets at fair value change through profit or loss														-40
equity-settled share-based compensation expenses														14,958
decrease of pledged deposits														-72
proceeds from disposal of items of property, plant and equipment														26
purchase of financial assets at fair value through profit or loss														-50,000
cash received from withdrawal of financial assets at fair value through profit or loss
cash receipts from investment income
addition of time deposits														-267,710
payments of expenses for issuance convertible redeemable preferred shares
proceeds from exercise of share option and restricted share units														4,099
net (decrease) / increase in cash and cash equivalents
less: pledged short-term deposits															455,744	0	256,000	-429,616	174,000
write-down of inventories to net realizable value
decrease of pledged short-term deposits
purchase of financial investment measured at amortized cost
proceeds from issuance of ordinary shares relating to private placement for an institutional investor
proceeds from exercise of share option
income from disposal of property, plant and equipment
decrease/(increase) in prepayments, other receivables and other assets
(increase)/decrease in inventories
(decrease)/increase in trade and notes payables
(decrease)/increase in other payables and accruals
net cash flows used in operating activities
net cash flows used in investing activities
net (decrease)/increase in cash and cash equivalents																	-43,730,000
provision for/ (reversal of) for the impairment of trade receivables
foreign currency exchange gain
increase of pledged short-term deposits
cash (used in) /from operations
net cash flow (used in)/from operating activities
net cash flows (used in)/from operating activities
addition of short-term time deposits
decrease in short-term deposits
addition of pledged short-term deposits
decrease in pledged short-term deposits
cash flows (used in)/generated from operating activities
cash flows from/(used in) financing activities																			-450,140,000
net increase/(decrease) in cash and cash equivalents

Legend Biotech Corporation(NASDAQ:LEGN)

Legend Biotech Corporation
(NASDAQ:LEGN)